# Saruparib

Source: https://onco.cc/drugs/saruparib/  
OnCo record `saruparib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Saruparib is an experimental small-molecule drug from AstraZeneca in phase 3 trials for prostate cancer, ovarian cancer and non-small-cell lung cancer, aimed at PARP.

## Summary

Saruparib (AZD5305) is a small-molecule drug developed by AstraZeneca. Its target is PARP (the sponsor names PARP (poly(ADP-ribose) polymerase)). The sponsor states: Saruparib (AZD5305) is an oral PARP inhibitor, studied added to androgen deprivation therapy (with or without abiraterone) in patients with BRCA-mutated prostate cancer. It is the investigational product in 4 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT06952803 (A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation) and NCT06120491 (Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents), in prostate cancer, ovarian cancer, non-small-cell lung cancer and endometrial cancer. The largest, NCT06120491, plans to enrol 1898 participants (actual) with primary completion expected 2027-09-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Code: AZD5305
- Modality: small molecule
- Mechanism: Saruparib (AZD5305) is an oral PARP inhibitor, studied added to androgen deprivation therapy (with or without abiraterone) in patients with BRCA-mutated prostate cancer.

## Sources

- ClinicalTrials.gov: trials of Saruparib: https://clinicaltrials.gov/search?intr=AZD5305

## Connected records

- cancers: [Advanced or recurrent endometrial cancer](https://onco.cc/cancers/advanced-recurrent-endometrial-cancer/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-mcrpc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Platinum-sensitive ovarian cancer](https://onco.cc/cancers/platinum-sensitive-ovarian-cancer/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- targets: [PARP](https://onco.cc/targets/parp/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- trials: [A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies](https://onco.cc/trials/nct05123482/), [A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation](https://onco.cc/trials/nct06952803/), [A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs](https://onco.cc/trials/nct07336446/), [Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors](https://onco.cc/trials/nct05797168/), [Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer](https://onco.cc/trials/nct06380751/), [Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents](https://onco.cc/trials/nct06120491/), [Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours](https://onco.cc/trials/nct07446855/), [Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies](https://onco.cc/trials/nct04644068/), [Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer](https://onco.cc/trials/nct05367440/)

---
JSON: https://onco.cc/api/v1/entities/saruparib.json